Lobbying client

ATRICURE

Biotechnology company for the treatment of atrial fibrillation and related conditions

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 4 of its records are shown together here.

Filings
28
Filed by
4
Reported in-house
—
Reported by firms
$364,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2021 to 2026

Filings

28 filings, newest first.
Filing Filed by Amount
Registration
1st Quarter 2023
FOLEY HOAG LLP — reported
4th Quarter - Report (No Activity)
4th Quarter 2022
HANCE SCARBOROUGH $20,000 reported
3rd Quarter - Report
3rd Quarter 2022
HANCE SCARBOROUGH $10,000 reported
2nd Quarter - Report
2nd Quarter 2022
HANCE SCARBOROUGH $10,000 reported
Registration
2nd Quarter 2022
HANCE SCARBOROUGH — reported
3rd Quarter - Termination (No Activity)
3rd Quarter 2021
DLA PIPER LLP (US) — reported
2nd Quarter - Report
2nd Quarter 2021
DLA PIPER LLP (US) $50,000 reported
Registration
2nd Quarter 2021
DLA PIPER LLP (US) — reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
FOLEY HOAG LLP 15 $274,000
DLA PIPER LLP (US) 2 $50,000
HANCE SCARBOROUGH 5 $40,000
POLSINELLI PC 1 —

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Medicare/Medicaid MMM 21
Copyright/Patent/Trademark CPT 2

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
S. 1260 117th 1

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.